Related Experiment Video
Updated: Nov 19, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive
Kyung Ho Lee1, Won-Myong Bahk2, Soo-Jung Lee2
1Departments of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Objective:
We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice.
Methods:
Nine patients were prescribed NeuropharmagenⓇ for selection of antidepressants for individual patient and their clinical outcomes were followed.
Results:
After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients.
Conclusion:
Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...

